Francesca Palandri: New Insights Into Anemia Management in Myelofibrosis
Francesca Palandri, Hematologist at IRCCS Sant’Orsola Polyclinic – Bologna University Hospital, shared on LinkedIn about a recent article she and her colleagues co-authored, published in European Journal of Haematology, adding:
”New in the European Journal of Haematology: hemoglobin ≥10 g/dL as a survival-linked treatment target in myelofibrosis.
Francesca Palandri, Casey O’Connell, Pankit Vachhani, Donal McLornan, Steffen Koschmieder, Hernandez Boluda Juan Carlos, Kazuya Shimoda, William Shiyuan Zhang, Catherine Ellis, Jasmine Sahni, and Vikas Gupta analyzed post hoc data from the SIMPLIFY-1 and MOMENTUM phase 3 trials in myelofibrosis patients with anemia.
The findings:
- 63% of JAK inhibitor-naive patients reached Hb ≥10 g/dL by week 24, versus 36% of JAK inhibitor-experienced patients.
- Patients with moderate anemia at baseline hit that threshold faster and more often than patients with severe anemia.
- Reaching Hb ≥10 g/dL tracked with longer survival across both trials.
Take action:
- Treat anemia early — don’t wait for it to become severe.
- Set Hb ≥10 g/dL as a concrete treatment target, not just a lab value to monitor.
- Track transfusion independence alongside Hb — both matter for outcomes.
Note: this is a descriptive, exploratory analysis
Thank you to all the patients who made this study possible, and to IRCCS Sant’Orsola Polyclinic – Bologna University Hospital, Alma Mater Studiorum – University of Bologna, and AIL Bologna for their continued support of research.”
Title: Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM Trials
Authors: Francesca Palandri, Casey O’Connell, Pankit Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernandez-Boluda, Kazuya Shimoda, Shiyuan Zhang, Catherine Ellis, Jessica Lim, Jasmine Sahni, Vikas Gupta
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question